Blood plasma is a crucial component of human blood, constituting about 55% of its total volume. It serves as a transport medium, carrying nutrients, hormones, and waste products throughout the body. Plasma plays a pivotal role in maintaining homeostasis by regulating blood pH and osmotic pressure. It contains essential proteins such as albumin, immunoglobulins, and clotting factors that contribute to various physiological functions, such as immune response and blood clotting.
Access Full Report at https://www.databridgemarketresearch.com/ar/reports/malaysia-blood-plasma-market
Data Bridge Market Research analyses that the Malaysia Blood Plasma Market which was USD 3,372 million in 2022, is expected to reach USD 6,521 million by 2030, and is expected to undergo a CAGR of 4.20 % during the forecast period from 2023-2030. The Malaysian government has played a pivotal role in fortifying the healthcare sector through supportive policies and initiatives. By implementing measures to enhance the availability of essential medical products, particularly in the blood plasma market, they have stimulated growth.
Key Findings of the Study
Technological advancement with its improved advancements is expected to drive the market's growth rate
In the Malaysian blood plasma market, technological advancements have emerged as a key driver, revolutionizing the entire plasma supply chain. The integration of automated systems has streamlined the collection, processing, and storage of blood plasma, enhancing overall efficiency. Improved testing methodologies contribute to higher accuracy and reliability of plasma-derived products. Additionally, advancements in plasma fractionation processes have bolstered accessibility and production reliability, thereby fueling market growth. These innovations not only elevate the quality of plasma-based products but also make them more readily available, meeting the increasing demand in Malaysia's healthcare landscape.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Hyperimmune Globulin, Albumin, Factor VIII, Factor IX, Immunoglobulin, Others), Mode of Delivery (Infusion Solutions, Gels, Sprays, Biomedical Sealants), Therapeutic Indication (Immunology, Oncology, Pulmonology, Rheumatology, Transplantation, Neurology, Hematology, Other), Application (Hypogammaglobulinemia, Immunodeficiency Diseases, Hemophilia, Von Willebrand's Disease (vWD), Others), End-User (Clinics, Hospitals, Other)
|
|
Market Players Covered
|
CSL Limited (Australia), Grifols, S.A.(Spain), Takeda Pharmaceutical Company Limited (Japan) and Octapharma AG (Switzerland)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Malaysia blood plasma market is segmented on the basis of type, mode of delivery, therapeutic indication, application, and end-user.
- On the basis of type, the Malaysia blood plasma market is classified into hyperimmune globulin, albumin, factor VIII, factor IX, immunoglobulin, and others
- On the basis of mode of delivery, the Malaysia blood plasma market is classified into infusion solutions, gels, sprays, and biomedical sealants
- On the basis of therapeutic indication, the Malaysia blood plasma market is classified into immunology, oncology, pulmonology, rheumatology, transplantation, neurology, hematology, and other
- On the basis of application, the Malaysia blood plasma market is classified into hypogammaglobulinemia, immunodeficiency diseases, hemophilia, von willebrand's disease (VWD), and others
- On the basis of end-user, the Malaysia blood plasma market is classified into clinics, hospitals, and other
Major Players
Data Bridge Market Research recognizes the following companies as the major Malaysia blood plasma market players in Malaysia blood plasma market are CSL Limited (Australia), Grifols, S.A.(Spain), Takeda Pharmaceutical Company Limited (Japan) and Octapharma AG (Switzerland)
Market Developments
- In June 2023, Grifols commenced the marketing of XEMBIFY, a 20% subcutaneous immunoglobulin, in Spain. This represents a significant milestone for Grifols as it introduces an advanced immunoglobulin therapy to the Spanish market. XEMBIFY, known for its high concentration of immunoglobulins, is designed for subcutaneous administration, offering patients a convenient and effective treatment option. This strategic move aligns with Grifols' commitment to providing innovative solutions in the field of immunology and reinforces its presence in the healthcare landscape
- In May 2023, Teva Pharmaceutical Industries Ltd. has unveiled a comprehensive strategic framework featuring four key pillars aimed at positioning the company for a transformative phase of blood plasma market growth. This strategic initiative seeks to strengthen the company's robust commercial portfolio, highlighted by key products such as AUSTEDO, AJOVY, UZEDYTM, and biosimilars. Additionally, the strategy focuses on enhancing its innovative pipeline, sustaining its leadership in the generics market, and streamlining business operations
- In February 2023, GC Biopharma successfully completed the acquisition of Catalyst Biosciences' rare disease hematology pipeline, gaining ownership of key assets, including "Marzeptacog alfa." Marzeptacog alfa, positioned at a Phase 3-ready stage, represents a promising engineered factor VIIa with demonstrated efficacy and safety in treating rare bleeding disorders. This acquisition underscores GC Biopharma's dedication to advancing therapies for rare diseases, particularly in the field of hematology. With a Phase 3-ready candidate in its portfolio, GC Biopharma is poised to contribute significantly to the development of novel treatments addressing unmet medical needs in the rare disease community
- In November 2022, a wholly-owned subsidiary of Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, referred to as "Sun Pharma," including its subsidiaries and/or associate companies) announced a significant development. This involved collaboration with Sun Pharma Advanced Research Company Ltd., underscoring their joint efforts in advancing pharmaceutical research and development in blood plasma market
- In March 2020, Grifols, S.A. made a significant announcement regarding its collaboration with prominent U.S. health entities, including the Biomedical Advanced Research and Development Authority (BARDA) and the Food and Drug Administration (FDA). This strategic partnership aimed to strengthen the formal ties between Grifols and these key organizations. The primary objective of this collaboration was to undertake an initiative focused on collecting plasma from individuals who had recovered from COVID-19, referred to as convalescent patients
For more detailed information about the Malaysia blood plasma market report, click here – https://www.databridgemarketresearch.com/ar/reports/malaysia-blood-plasma-market
